A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL TRIAL OF TRASTUZUMAB DERUXTECAN VERSUS STANDARD OF CARE CHEMOTHERAPY WITH OR WITHOUT RADIOTHERAPY AS ADJUVANT TREATMENT FOR HER2-EXPRESSING (IHC 3+/2+) ENDOMETRIAL CANCER (DESTINY-ENDOMETRIAL02/ GOG-3122/ENGOT-EN30/GINECO)

Registry ID

DS8201-854

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

DAIICHI SANKYO INC

Start date

2026-06-22

Last update

2025-09-12

Conditions

• ENDOMETRIAL CANCER

Related clinical trials

• A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO INVESTIGATE GSK5733584 COMPARED WITH CHEMOTHERAPY IN PARTICIPANTS WITH RECURRENT ENDOMETRIAL CANCER
• A PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF RINATABART SESUTECAN (RINA-S) VERSUS TREATMENT OF INVESTIGATOR’S CHOICE (IC) IN PATIENTS WITH ENDOMETRIAL CANCER AFTER PLATINUM-BASED CHEMOTHERAPY AND PD(L)-1 THERAPY
• Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer
• A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO COMPARE THE EFFICACY AND SAFETY OF SACITUZUMAB TIRUMOTECAN IN COMBINATION WITH PEMBROLIZUMAB VERSUS PEMBROLIZUMAB ALONE AS FIRST-LINE MAINTENANCE TREATMENT IN PARTICIPANTS WITH MISMATCH REPAIR PROFICIENT ENDOMETRIAL CANCER (TROFUSE-033/GOG-3119/ENGOT-EN29)
• A PHASE III, RANDOMIZED, MULTI-SITE, OPEN-LABEL TRIAL OF BNT323/DB-1303 VERSUS INVESTIGATOR¿S CHOICE OF CHEMOTHERAPY IN PREVIOUSLY TREATED PATIENTS WITH HER2- EXPRESSING RECURRENT ENDOMETRIAL CANCER
• A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF SACITUZUMAB GOVITECAN VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PARTICIPANTS WITH ENDOMETRIAL CANCER WHO HAVE RECEIVED PRIOR PLATINUM-BASED CHEMOTHERAPY AND ANTI-PD-1/PD-L1 IMMUNOTHERAPY

View on source registry